5-HT receptor

Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference

Retrieved on: 
Thursday, September 29, 2022
Securities Exchange Act of 1934, American Academy, Inflammation, AAO, ASCRS, Academy, American Society of Cataract and Refractive Surgery, Twitter, NYSE, Retina, FDA, Refractive surgery, PTN, Drug Quality and Security Act, Duane syndrome, Association, Society, Private Securities Litigation Reform Act, Partnership, Securities Act of 1933, Calendar, DED, Metabolism, Biology, U.S. Securities and Exchange Commission, Patient, Melanocortin, Eye, Physician, Technology, Quality of life, Cataract, Tissue, Surgeon, Genomics, Biotechnology, Security (finance), Proteomics, Marketing, American Academy of Ophthalmology, Multimedia, 5-HT receptor, Kidney, Education, View, Video game, Pharmaceutical industry, Hospital, Palatine (disambiguation), Bremelanotide

CRANBURY, N.J., Sept. 29, 2022 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced that Paul Kayne, Ph.D., Vice President of Biological Sciences at Palatin, presented today at the Eyecelerator@AAO in Chicago, IL. The presentation was one of several in the "Eyecelerator@ AAO 2022 - Therapeutics Showcase" general session.

Key Points: 
  • The presentation was one of several in the "Eyecelerator@ AAO 2022 - Therapeutics Showcase" general session.
  • For additional information regarding Palatin, please visit Palatin's website at www.Palatin.com and follow Palatin on Twitter at @PalatinTech.
  • Palatin is not responsible for updating for events that occur after the date of this press release.
  • Palatin Technologies and Vyleesi are registered trademarks of Palatin Technologies, Inc.
    View original content to download multimedia: https://www.prnewswire.com/news-releases/palatin-announces-presentation-...

Palatin to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference

Retrieved on: 
Monday, May 2, 2022
COVID-19, Calendar, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Pain, 5-HT receptor, Securities Exchange Act of 1934, Biotechnology, NDA, Kidney, Red, Physician, ARVO, Securities Act of 1933, Eye, Irritation, Metabolism, Patient, Security (finance), Conjunctiva, Clinical trial, Animal, Program, FDA, DED, Inflammation, Drug Quality and Security Act, Dry, Tissue, Quality of life, Marketing, Cornea, Disease, Melanocortin, View, Technology, Research, Multimedia, Lubrication, Pharmaceutical industry, Bremelanotide, Palatine (disambiguation)

CRANBURY, N.J., May 2, 2022 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Conference being held May 1-4 in Denver.

Key Points: 
  • Palatin previously announced positive results in its Phase 2 study of PL9643 for the treatment of DED.
  • If the program progresses as planned, an NDA submission is targeted for the first half of calendar year 2024.
  • ARVO is the largest and most respected eye and vision research organization in the world.
  • Palatin is not responsible for updating for events that occur after the date of this press release.

Palatin to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022

Retrieved on: 
Thursday, April 21, 2022
NDA, CEO, Dry, Irritation, Cornea, Pain, Kidney, Biotechnology, ASCRS, Clinical trial, Melanocortin, Marketing, Inflammation, U.S. Securities and Exchange Commission, COVID-19, Security (finance), Eye, Duane syndrome, DED, Retina, Calendar, Private Securities Litigation Reform Act, Red, Education, Program, Drug Quality and Security Act, Patient, Conjunctiva, Tissue, Surgeon, Securities Exchange Act of 1934, Conference, Technology, 5-HT receptor, AAO, Metabolism, NYSE, American Academy of Ophthalmology, American Academy, Partnership, Physician, Multimedia, PTN, Academy, FDA, Quality of life, Disease, Ophthalmology, Securities Act of 1933, View, Lubrication, Association, Fine chemical, Pharmaceutical industry, Online shopping, Hospital, Bremelanotide, Palatine (disambiguation)

CRANBURY, N.J., April 21, 2022 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced that Carl Spana, Ph.D., President and CEO of Palatin, will deliver a presentation today at the Eyecelerator@ASCRS 2022 Conference in Washington D.C. 

Key Points: 
  • If the program progresses as planned, an NDA submission is targeted for the first half of calendar year 2024.
  • Palatin previously announced positive results in its Phase 2 study of PL9643 for the treatment of DED.
  • Eyecelerator, is a partnership between ASCRS and the American Academy of Ophthalmology (AAO) to connect entrepreneurs, investors, businesses, and ophthalmologists to accelerate ophthalmic innovation and improve patient outcomes.
  • Palatin is not responsible for updating for events that occur after the date of this press release.

Palatin Awarded "Top 10 Poster" Designation at the American Society of Retina Specialists (ASRS) 2021 Annual Meeting

Retrieved on: 
Friday, October 22, 2021
PTN, Bremelanotide, Diabetic retinopathy, Annual general meeting, Research, Biotechnology, Inflammation, Technology, Poster, Retina, Securities Act of 1933, 5-HT receptor, ASRS, Drug development, Security (finance), U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, FDA, View, NYSE, Eye, Retinopathy, Melanocortin, Kidney, Senior, Marketing, CEO, Tissue, Multimedia, Metabolism, Drug Quality and Security Act, Doctor of Philosophy, Securities Exchange Act of 1934, Choroidal neovascularization, Society, Fine chemical, Pharmaceutical industry

"We are honored to have our poster recognized by ASRS as a Top 10 poster," said John Dodd, PhD, Senior Vice President of Preclinical Research at Palatin.

Key Points: 
  • "We are honored to have our poster recognized by ASRS as a Top 10 poster," said John Dodd, PhD, Senior Vice President of Preclinical Research at Palatin.
  • "It speaks to the interest and enthusiasm in the scientific community about the potential of the melanocortin mechanism to treat inflammatory conditions.
  • We are excited to share this retina and other inflammatory disease model data where we see melanocortin agonists work so well."
  • Palatin is not responsible for updating for events that occur after the date of this press release.

Palatin Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting

Retrieved on: 
Monday, September 27, 2021
Biotechnology, Securities Act of 1933, Melanocortin, 5-HT receptor, Security (finance), Inflammation, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, FDA, Multimedia, Metabolism, Kidney, Marketing, Technology, View, Tissue, Securities Exchange Act of 1934, Eye, Pharmaceutical industry

The melanocortin receptor ("MCr") system has effects on inflammation, immune system responses, metabolism, food intake, and sexual function.

Key Points: 
  • The melanocortin receptor ("MCr") system has effects on inflammation, immune system responses, metabolism, food intake, and sexual function.
  • Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have medically significant pharmacological effects.
  • Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential.
  • Palatin is not responsible for updating for events that occur after the date of this press release.

NeonMind to Present at the Benzinga Global Small Cap Conference

Retrieved on: 
Monday, May 10, 2021
Branches of biology, Hallucinations, Psychedelic drugs, Organophosphates, Serotonin receptors, Neurochemistry, Psilocybin, Hallucinogen, Serotonin, 5-HT receptor

b"The Benzinga Global Small Cap Conference is designed to bridge the gap between Small Cap publicly traded companies, investors, and traders.

Key Points: 
  • b"The Benzinga Global Small Cap Conference is designed to bridge the gap between Small Cap publicly traded companies, investors, and traders.
  • By bringing together over 60 high-growth companies, Benzinga offers the opportunity to gain insights on Small Cap companies across a wide range of industries through live company presentations and educational sessions hosted by executives, expert traders and analysts.\nNeonMind is engaged in developing clinical treatments and wellness products to address obesity and weight management conditions and to promote health and wellness.
  • In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity.
  • NeonMind's first drug candidate employs psilocybin as an agonist to the serotonin receptor 5- HT2A, which is involved in the hallucinogenic effect of psychedelics.

5-Hydroxytryptamine Receptor 6, Pipeline Review, H2 2019 - Alla Chem LLC, HEC Pharm Co Ltd & Reviva Pharmaceuticals Inc - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 21, 2020
Health, Pharmaceutical, Serotonin receptors, Branches of biology, Cell signaling, Serotonin, 5-HT6 receptor, 5-HT receptor, Neurotransmitter, 5-HT5A receptor, 5-HT2 receptor

The "5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report '5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2019'; 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) pipeline Target constitutes close to 15 molecules.
  • Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - The 5-HT6 receptor is a subtype of 5-HT receptor that binds the endogenous neurotransmitter serotonin.